Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.

Psoriasis drug may help fight coronary plaques

10 Feb 2019

Biologic therapies for severe psoriasis appear to help reduce noncalcified coronary plaques and improve plaque morphology, a recent study has shown.

Researchers conducted a prospective observational study including 121 psoriasis patients, of whom 89 received biologic treatments (mean age 49.1±12.2 years; 56 percent male) and 32 (mean age 51.2±12.0 years; 63 percent male) were treated with other agents. Participants tended to have low cardiovascular risk (median Framingham score, 3) with moderate-to-severe skin disease (median Psoriasis Area and Severity Index [PASI], 8.6).

After a year of follow-up, patients who were treated with biologic agents showed significant improvements in the PASI score (64-percent improvement, p<0.001), as well as a significant reduction in high-sensitivity C-reactive protein levels (p<0.001). No such changes were observed in the comparison group.

Moreover, a 5-percent decrease in total coronary plaque burden was observed in participants on biologic therapy (p=0.009), an effect primarily driven by a drop in the noncalcified plaque burden (p=0.005). No improvements in fibrous burden (p=0.71) were reported, though fibro-fatty (p=0.004) and necrotic (p=0.03) burdens decreased.

In comparison, those receiving nonbiologic interventions showed no significant 1-year change in total plaque burden (p=0.22), noncalcified plaque burden (p=0.17) and fibrous burden (p=0.22). There was also an increase in fibro-fatty burden (p=0.004).

Intergroup comparisons showed that the 1-year reduction in noncalcified plaque was significantly greater in patients treated with biologic agents (p=0.03) even after adjustments for cardiovascular risk factors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.